Why cancer patients are flying to China for treatment

An Australian woman with terminal blood cancer flew to Shanghai, spent roughly AUD 110,000, and seven months later her doctors could find no trace of the disease.

Story Snapshot

CAR-T cell therapy in China costs 60–70% less than in the US, and the treatment is ready in 8 days versus 2–3 months in America.
Amanda Harvey, an Australian multiple myeloma patient, achieved complete remission seven months after treatment at a Shanghai hospital.
China now leads the world in the number of active CAR-T clinical trials, despite approving its first therapy four years after the US.
Real risks exist: relapse rates of 30–60% are documented, and severe immune reactions occur in roughly one in three patients in some studies.

What CAR-T Therapy Actually Does

Chimeric antigen receptor T-cell therapy, known as CAR-T, takes a patient’s own immune cells, re-engineers them in a lab to hunt cancer, and puts them back in the body. It is not chemotherapy. It is not radiation. It is a living drug built from your own biology. For blood cancers like multiple myeloma and certain lymphomas that have stopped responding to everything else, it has produced results that older treatments simply cannot match.

China approved its first CAR-T product in 2021, four years behind the United States. But the country moved fast after that. It now leads the world in active CAR-T clinical trials. Ruijin Hospital in Shanghai reported an 88% positive response rate among 17 patients with relapsed or hard-to-treat multiple myeloma in a domestic immunotherapy trial. That is not a fringe result from an unknown clinic. Ruijin’s international services division has treated more than 80,000 overseas patients since 1998.

The Cost Gap Is Not a Rounding Error

In the United States, commercial CAR-T therapy runs between $373,000 and $475,000. In China, the same category of treatment costs $120,000 to $170,000. Amanda Harvey put it plainly: her total bill in Shanghai came to roughly AUD 110,000, excluding travel. She estimated the same treatment would cost around AUD 1 million in the US or UK. That is not a modest discount. That is the difference between treatment and bankruptcy — or treatment and death for patients who cannot crowdfund a million dollars while their cancer progresses.

Eight Days Versus Three Months Changes Everything

The manufacturing timeline may matter even more than the price. In the US, producing a patient’s custom CAR-T cells takes two to three months. In China, it takes eight days. For a patient with aggressive, relapsed multiple myeloma, two to three months is not a wait. It is a sentence. Patients who are progressing too fast to survive the American manufacturing window have a real option in China that does not exist at home. That is not marketing. That is biology and logistics colliding in a way that determines who lives.

The Risks Are Real and Deserve Honest Attention

None of this means China’s CAR-T programs are without serious problems. Severe immune overreaction, called cytokine release syndrome, occurs in roughly 29–38% of patients in some trial data. Relapse rates after CAR-T therapy for blood cancers run between 30–60% even when initial response is strong. Most Chinese CAR-T trials are single-arm studies without control groups, which makes direct comparison to Western outcomes genuinely difficult. Researchers have noted that drawing firm conclusions about equal effectiveness between Chinese and American protocols is not yet supported by the available data.

The patient stories — Harvey’s remission, and others like South African athlete Oscar Chalupsky who sought treatment in Shanghai after conventional therapies in Germany failed — are compelling. But they are individual accounts, not controlled studies. Long-term survival data for international patients treated in China has not been published in peer-reviewed journals. Total costs, once travel, accommodation, and follow-up care are added, narrow the price gap considerably. These are not reasons to dismiss what is happening in Shanghai. They are reasons to demand better data, which neither Chinese hospitals nor Western health authorities have yet provided.

Why Western Institutions Are Slow to Engage

No Australian, American, or British health authority has published official guidance on seeking CAR-T treatment in China. Insurance coverage does not follow patients across borders. The Food and Drug Administration (FDA) and the European Medicines Agency do not automatically recognize approvals from China’s National Medical Products Administration. Some of that institutional caution reflects genuine scientific standards. But it is also worth noting that US commercial CAR-T prices are three to four times higher than China’s. The companies holding those prices — including major pharmaceutical firms — have a direct financial interest in patients not looking east. That conflict does not prove bad faith, but it should be part of how people weigh the silence from official channels.

What Patients Facing This Decision Actually Need

The question is not whether China’s CAR-T programs are perfect. They are not. The question is whether a patient with relapsed multiple myeloma who cannot afford $400,000 and cannot survive a three-month wait should be told their only option is to go home and get comfortable. That framing — where the experimental risk is flying to Shanghai, but the acceptable path is doing nothing — deserves serious scrutiny. More peer-reviewed outcome data from Chinese hospitals, independent verification of remission claims, and transparent adverse event reporting would help everyone make better decisions. Until that data exists, patients will keep boarding planes and making their own calculations.